The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 04, 2018

Filed:

Oct. 17, 2014
Applicants:

National University of Singapore, Singapore, SG;

St. Jude Children's Research Hospital, Memphis, TN (US);

Unum Therapeutics Inc., Cambridge, MA (US);

Inventors:

Dario Campana, Singapore, SG;

Ko Kudo, Shizuoka, JP;

Charles Wilson, Cambridge, MA (US);

Kathleen McGinness, Cambridge, MA (US);

Assignees:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/735 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C07K 16/32 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); A61K 39/395 (2006.01); A61K 35/17 (2015.01); A61K 39/00 (2006.01); A61K 38/00 (2006.01);
U.S. Cl.
CPC ...
C07K 14/70535 (2013.01); A61K 35/17 (2013.01); A61K 39/39558 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70578 (2013.01); C07K 16/2887 (2013.01); C07K 16/3084 (2013.01); C07K 16/32 (2013.01); A61K 38/00 (2013.01); A61K 2039/515 (2013.01); A61K 2039/572 (2013.01); C07K 2319/00 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C07K 2319/32 (2013.01); C07K 2319/90 (2013.01); C12N 2740/13043 (2013.01);
Abstract

Disclosed herein are chimeric receptors comprising an extracellular domain with affinity and specific for the Fc portion of an immunoglobulin molecule (Ig) (e.g., an extracellular ligand-binding domain of F158 FCGR3A or V158 FCGR3A variant); a transmembrane domain (e.g., a transmembrane domain of CD8α); at least one co-stimulatory signaling domain (e.g., a co-stimulatory signaling domain of 4-1BB); and a cytoplasmic signaling domain comprising an immunoreceptor tyrosine-based activation motif (ITAM) (e.g., a cytoplasmic signaling domain of CD3ζ). Also provided herein are nucleic acids encoding such chimeric receptors and immune cells expressing the chimeric receptors. Such immune cells can be used to enhance antibody-dependent cell-mediated cytotoxicity and/or to enhance antibody-based immunotherapy, such as cancer immunotherapy.


Find Patent Forward Citations

Loading…